In this study, obesity induced T2DM mice that received chronic administration of our novel GPR119 agonist, HD0471953, showed improved insulin sensitivity and glycemic control without severe hypoglycemia. Here, GPR119 is linked to obesity due to melanocortin 4 receptor deficiency.